Jiang Min Wei
Amministratore Delegato presso COLAND HOLDINGS LIMITED
Provenienza dei contatti di primo grado di Jiang Min Wei
Entità | Tipo di entità | Settore Industriale | |
---|---|---|---|
Shanghai Guo Chuang Pharmaceutical Co., Ltd.
Shanghai Guo Chuang Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Shanghai Guo Chuang Pharmaceutical Co., Ltd. principally engages in the research, development, production, and sale of pharmaceutical products. Its products include pharmaceuticals against nervous system diseases, digestive system diseases, cardiovascular diseases, mental diseases, and immune system diseases. The company was founded on March 20, 2003 and is headquartered in Shanghai, China.
14
| Holding Company | Pharmaceuticals: Major | 14 |
Private Company | Pharmaceuticals: Major | 9 | |
Heilongjiang Province Tongze Pharmaceutical Co. Ltd.
1
| Private Company | 1 | |
Heilongjiang University of Chinese Medicine
1
| College/University | Other Consumer Services | 1 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Jiang Min Wei tramite i suoi contatti personali
Società | Settore | Persone collegate | Posizione principale |
---|---|---|---|
Roche (China) Co. Ltd. | Corporate Officer/Principal Corporate Officer/Principal Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer | ||
Peking University
Peking University Other Consumer ServicesConsumer Services Peking University provides post-secondary education services. It offers undergraduate and graduate courses. It provides courses such as basic and applied sciences, social sciences and the humanities, sciences of medicine, management, and education. The company was founded by JiaNai Sun in 1898 and is headquartered in Beijing, China. | College/University | Masters Business Admin Doctorate Degree Doctorate Degree | |
Coland Pharmaceutical Co., Ltd.
Coland Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Coland Pharmaceutical is a specialty pharmaceutical company focusing on marketing branded products and developing solid pipelines through collaboration with leading institutes. Its main interests are in the dedicated therapeutic areas Hepatitis, Immunology, Oncology, and other niche areas. Coland was started its sales operation in 2005. Daiding (Adefovir), a first-to-market generic that treats HBV was launched in 2005. With effective promotion, and brand building, Daiding achieved great success and gained the leading position in China. Its goal is to become a leading specialty pharmaceutical company in China with strong sales and marketing capabilities and solid product pipelines. The company was founded in 2003 and is headquartered in Shanghai, China. | Pharmaceuticals: Major | Chairman Director/Board Member Director/Board Member | |
HUA MEDICINE (SHANGHAI) LTD. | Pharmaceuticals: Major | Director/Board Member Founder | |
Coland Development Co. Ltd. | Chairman Director/Board Member | ||
Hoffmann-La Roche, Inc.
Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal | |
Hainan Quanyuan Pharmaceutical Co. Ltd.
Hainan Quanyuan Pharmaceutical Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of Coland Holdings Ltd., Hainan Quanyuan Pharmaceutical Co. Ltd. is a Chinese company that manufactures pharmaceutical products. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
National Taiwan University | College/University | Undergraduate Degree Undergraduate Degree | |
The University of Chicago | College/University | Masters Business Admin Graduate Degree | |
Auspicious Day Group Ltd. | Director/Board Member | ||
Dairy Farm China | Corporate Officer/Principal | ||
Procter & Gamble Taiwan Ltd.
Procter & Gamble Taiwan Ltd. Household/Personal CareConsumer Non-Durables Part of Procter & Gamble Co., Procter & Gamble Taiwan Ltd. is a manufacturer of family household and personal care products. | Household/Personal Care | Corporate Officer/Principal | |
Shechen Pharmaceutical Co. Ltd. | Director/Board Member | ||
CIDC Consultants, Inc.
CIDC Consultants, Inc. Investment ManagersFinance CIDC Consultants, Inc. (CIDC Consultants) is an independent, Taiwan-based venture capital firm which was established in 1988 to offer management consulting, serve as an intermediary for domestic and foreign investment, facilitate investment-related technology cooperation, provide business intelligence and deliver inquiry services for venture capital firms. Located in Taipei, the firm manages funds backed by Taiwanese companies in a range of industries and works with European and American partners to make joint investments. CIDC has a cooperative relationship with Doughty Hanson & Co. and their affiliate, Global Financial Services, helps their investee companies to establish sound financial systems. ? | Investment Managers | President | |
Hefei City Guozhen Pharmaceutical Sales Ltd. | Director/Board Member | ||
Exquisite Creation Ltd. | Director/Board Member | ||
Roche Pharmaceuticals, Inc.
Roche Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Roche Pharmaceuticals provides research and development services in the fields of pharmaceuticals and diagnostics. It also provides diagnostics and drugs for cancer and transplantation. The company is headquartered in Nutley, NJ. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Schering-Plough Shanghai Trading Co. Ltd. | Director/Board Member | ||
BORA PHARMACEUTICALS CO., LTD. | Pharmaceuticals: Other | Director/Board Member | |
Sunyou Group Holdings Ltd. | Director/Board Member | ||
Central Chief Ltd.
Central Chief Ltd. Financial ConglomeratesFinance Part of Coland Holdings Ltd., Central Chief Ltd. operates as an investment holding Caymanian company. | Financial Conglomerates | Director/Board Member | |
Shanghai Teresa Healthcare Sci-Tech Co. Ltd.
Shanghai Teresa Healthcare Sci-Tech Co. Ltd. Medical SpecialtiesHealth Technology Part of Immuno Cure Biotech Ltd., Shanghai Teresa Healthcare Sci-Tech Co. Ltd. manufactures medical electroporation devices. The private company is based in Shanghai, China. Shanghai Teresa Healthcare Sci-Tech Co. was acquired by Immuno Cure Biotech Ltd. on September 20, 2022. The Chinese company was founded in 2004. The CEO is Liye Chen. | Medical Specialties | Director/Board Member | |
Sunyou Holdings Ltd. (BVI) | Director/Board Member | ||
Hung Chun Bio-S Co. Ltd.
Hung Chun Bio-S Co. Ltd. Industrial MachineryProducer Manufacturing Hung Chun Bio-S Co. Ltd. is a biotechnology and medical equipment company located in the southern science and industrial park in Kaohsiung City, Taiwan. The Taiwanese company's research team was established in 1995 and has since been developing implantable medical equipment. The private company has obtained medical equipment GMP certification, as well as the third-level implantation artificial dentition domestic health department product inspection registration, the US FDA, and the EU CE certification. The company is the first domestic artificial dental root professional design and development and manufacturing plant. | Industrial Machinery | Director/Board Member | |
Tongji University | College/University | Corporate Officer/Principal | |
Iowa State University | College/University | Doctorate Degree | |
Shanghai LIDE Biotech Co. Ltd.
Shanghai LIDE Biotech Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Shanghai LIDE Biotech Co. Ltd. is a translational medicine service provider that specializes in oncology translational research and immuno oncology. The private company is based in Shanghai, China. The Chinese company has a growing bank of over 50 cell line-derived xenograft (cdx) mouse models that are used for preclinical drug efficacy testing. The benefits of cdx models are their cost effectiveness, fast turnaround time, and high efficiency of xenotransplantation. LIDE's FGI (Functional Genomic Imaging) platform leverages its K-cell technology and bioinformatics team to deliver next-generation transcription analysis. The primary benefit of CR (Conditionally Reprogrammed) cells is their intratumor and intertumor heterogeneity, even after amplification. | Miscellaneous Commercial Services | Director/Board Member | |
China Pharmaceutical University | College/University | Doctorate Degree | |
Shanghai Ocean University | College/University | Undergraduate Degree | |
Nanjing University | College/University | Masters Business Admin | |
Tsinghua University | College/University | Masters Business Admin | |
GOOGOL TECHNOLOGY CO., LTD. | Electrical Products | Director/Board Member | |
SHANGHAI RENDU BIOTECHNOLOGY CO., LTD. | Medical Specialties | Director/Board Member | |
Jilin University | College/University | Undergraduate Degree | |
DIAN DIAGNOSTICS GROUP CO.,LTD. | Medical/Nursing Services | Director/Board Member | |
HBM HOLDINGS LIMITED | Pharmaceuticals: Other | Director/Board Member | |
East China Normal University | College/University | Corporate Officer/Principal | |
HANGZHOU TIGERMED CONSULTING CO., LTD | Miscellaneous Commercial Services | Chairman | |
University of Oxford | College/University | Doctorate Degree | |
Zhengzhou University | College/University | Undergraduate Degree | |
Hua Medicine (Shanghai) Co., Ltd.
Hua Medicine (Shanghai) Co., Ltd. BiotechnologyHealth Technology Hua Medicine (Shanghai) Co., Ltd. is a Chinese biotechnology company that focuses on the clinical needs of diabetic patients. The private company is based in Shanghai, China. The company has brought together high-end talents and scientific and technological resources to develop the world's first dorzagliatin (hms5552) for the treatment of type 2 diabetes. Hua Medicine has conducted two phase III clinical trials in 2019, targeting type 2 diabetes patients who have failed to treat the disease with other medications. The company plans to expand the advanced concepts of personalized therapy and management of diabetes to achieve effective control of diabetes and metabolic diseases and complications. The company was founded in 2011 by Li Chen, who has been the CEO since then. | Biotechnology | Chief Executive Officer | |
Hua Medicine Technology (Hong Kong) Ltd. | Director/Board Member | ||
Roche R & D Center China Co. Ltd. | Chief Tech/Sci/R&D Officer | ||
Sino-American Pharmaceutical Professionals Association | President | ||
Sunyou Holdings Ltd. (Cayman) | Director/Board Member | ||
Feng Chia University | College/University | Undergraduate Degree | |
Business Enterprise Investments Group Ltd. | Director/Board Member | ||
ALEXION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Pharmaceutical Association of Shijiazhuang City | President |
Statistiche
Distribuzione geografica
Cina | 28 |
Taiwan | 10 |
Stati Uniti | 7 |
Regno Unito | 4 |
Hong Kong | 3 |
Settori
Consumer Services | 15 |
Health Technology | 11 |
Commercial Services | 4 |
Finance | 3 |
Producer Manufacturing | 3 |
Posizioni
Director/Board Member | 64 |
Corporate Officer/Principal | 23 |
Independent Dir/Board Member | 21 |
Undergraduate Degree | 10 |
Chairman | 8 |
Contatti più connessi
Insiders | |
---|---|
William Keller | 26 |
Hsin Lee | 17 |
Li Chen | 14 |
Jo Hua Tsao | 13 |
Li Yan Chang | 11 |
Jen Lin Shen | 9 |
Xiao Ping Ye | 9 |
Ruo Hua Cao | 4 |
Lu Zhang | 3 |
Ling Jin | 3 |
Qi Jia Liu | 2 |
Mei Fang Ma | 2 |
Yong Hua Wang | 2 |
Li Yang Shi | 2 |
Chun Pu Zou | 2 |
- Borsa valori
- Insiders
- Jiang Min Wei
- Connessioni Società